Follow
Panagiotis J Vlachostergios
Panagiotis J Vlachostergios
Division of Hematology and Medical Oncology, New York-Presbyterian / Weill Cornell Medical Center
Verified email at nyp.org
Title
Cited by
Cited by
Year
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets
MA Feitelson, A Arzumanyan, RJ Kulathinal, SW Blain, RF Holcombe, ...
Seminars in cancer biology 35, S25-S54, 2015
7112015
Designing a broad-spectrum integrative approach for cancer prevention and treatment
KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, ...
Seminars in cancer biology 35, S276-S304, 2015
3002015
Emerging variants of castration-resistant prostate cancer
PJ Vlachostergios, L Puca, H Beltran
Current oncology reports 19, 1-10, 2017
1872017
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling
BD Robinson, PJ Vlachostergios, B Bhinder, W Liu, K Li, TJ Moss, ...
Nature communications 10 (1), 2977, 2019
1652019
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD …
ES Antonarakis, P Isaacsson Velho, W Fu, H Wang, N Agarwal, ...
JCO precision oncology 4, 370-381, 2020
1642020
Bortezomib represses HIF-1á protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells
CD Befani, PJ Vlachostergios, E Hatzidaki, A Patrikidou, S Bonanou, ...
Journal of molecular medicine 90, 45-54, 2012
1512012
Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis
I Gioulbasanis, P Georgoulias, PJ Vlachostergios, V Baracos, S Ghosh, ...
Lung cancer 74 (3), 516-520, 2011
1102011
Neuroendocrine differentiation in prostate cancer: emerging biology, models, and therapies
L Puca, PJ Vlachostergios, H Beltran
Cold Spring Harbor perspectives in medicine 9 (2), a030593, 2019
972019
The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer
I Gioulbasanis, A Pallis, PJ Vlachostergios, A Xyrafas, Z Giannousi, ...
Lung Cancer 77 (2), 383-388, 2012
772012
Targeting neuroendocrine prostate cancer: molecular and clinical perspectives
PJ Vlachostergios, CN Papandreou
Frontiers in oncology 5, 6, 2015
732015
Fecal DNA testing for colorectal cancer screening: Molecular targets and perspectives
A Dhaliwal, PJ Vlachostergios, KG Oikonomou, Y Moshenyat
World journal of gastrointestinal oncology 7 (10), 178, 2015
632015
Elevated lactic acid is a negative prognostic factor in metastatic lung cancer
PJ Vlachostergios, KG Oikonomou, E Gibilaro, G Apergis
Cancer Biomarkers 15 (6), 725-734, 2015
602015
SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapy
V Conteduca, SY Ku, L Puca, M Slade, L Fernandez, J Hess, R Bareja, ...
Molecular cancer therapeutics 19 (5), 1157-1164, 2020
542020
Treatment resistance in urothelial carcinoma: an evolutionary perspective
PJ Vlachostergios, BM Faltas
Nature reviews Clinical oncology 15 (8), 495-509, 2018
532018
Orbital metastasis of breast carcinoma
PJ Vlachostergios, IA Voutsadakis, CN Papandreou
Breast cáncer: basic and clinical research 3, 117822340900300001, 2009
482009
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner
PJ Vlachostergios, E Hatzidaki, CD Befani, P Liakos, CN Papandreou
Investigational new drugs 31, 1169-1181, 2013
422013
The molecular limitations of biomarker research in bladder cancer
PJ Vlachostergios, BM Faltas
World journal of urology 37, 837-848, 2019
412019
Prostate-specific membrane antigen uptake and survival in metastatic castration-resistant prostate cancer
PJ Vlachostergios, MJ Niaz, M Sun, SA Mosallaie, C Thomas, PJ Christos, ...
Frontiers in oncology 11, 630589, 2021
392021
A broad-spectrum integrative design for cancer prevention and therapy
KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, ...
Seminars in cancer biology 35 (Suppl), S276, 2015
382015
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer
F Taza, AE Holler, W Fu, H Wang, N Adra, C Albany, R Ashkar, HH Cheng, ...
JCO Precision Oncology 5, 1200-1220, 2021
372021
The system can't perform the operation now. Try again later.
Articles 1–20